Sugentech, Inc. Logo

Sugentech, Inc.

An in-vitro diagnostics company that develops and commercializes diagnostic solutions.

253840 | KO

Overview

Corporate Details

ISIN(s):
KR7253840003
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노2로 206 사무동2층 수젠텍, 대전광역시

Description

Sugentech, Inc. is an in-vitro diagnostics (IVD) company that develops and commercializes diagnostic solutions by integrating biotechnology, nanotechnology, and information technology. The company's product portfolio serves diverse healthcare settings, from large hospitals and laboratories to smaller clinics and home users. Key offerings include automated multi-immunoblot systems, point-of-care testing (POCT) platforms, and self-diagnostic kits for personal use, such as ovulation and pregnancy tests. Sugentech leverages proprietary technologies in developing high-level antibodies and advanced nanoparticles to create highly sensitive and precise immunochemical assays, underpinning its digital healthcare diagnostic platform for personalized medicine.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-08 00:00
자기주식처분결과보고서
Korean 35.7 KB
2025-09-08 00:00
증권발행결과(자율공시)
Korean 6.2 KB
2025-08-29 00:00
주요사항보고서(교환사채권발행결정)
Korean 53.4 KB
2025-08-29 00:00
주요사항보고서(자기주식처분결정)
Korean 42.9 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.7 MB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 1.5 MB
2025-04-30 00:00
소속부변경
Korean 3.6 KB
2025-03-26 00:00
정기주주총회결과
Korean 30.2 KB
2025-03-26 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 11.3 KB
2025-03-18 00:00
[첨부추가]사업보고서 (2024.12)
Korean 663.6 KB
2025-03-11 00:00
감사보고서제출
Korean 25.0 KB
2025-03-10 00:00
[기재정정]의결권대리행사권유참고서류
Korean 176.4 KB
2025-03-07 00:00
주주총회소집결의
Korean 17.7 KB
2025-03-07 00:00
주주총회소집공고
Korean 167.5 KB
2025-03-07 00:00
의결권대리행사권유참고서류
Korean 170.6 KB

Automate Your Workflow. Get a real-time feed of all Sugentech, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sugentech, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sugentech, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.